Actively Recruiting
Randomized, Double-Blind Study of GSK5784283 Felcorekibart Compared to Placebo With Standard Care in Adults With Chronic Rhinosinusitis With Nasal Polyps
Led by GlaxoSmithKline · Updated on 2026-10-14
218
Participants Needed
3
Research Sites
34 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of GSK5784283, also known as Felcorekibart, as an add-on maintenance treatment for adults with chronic rhinosinusitis with nasal polyps CRSwNP. This phase 3 randomized, double-blind study compares GSK5784283 plus standard of care against placebo plus standard of care to assess improvements in nasal polyp scores and nasal obstruction symptoms. Participants receive either GSK5784283 or placebo alongside their standard treatment. The study runs for 52 weeks, during which nasal polyp size and symptoms like nasal obstruction, loss of smell, and overall quality of life are monitored. The trial also tracks the time until nasal surgery or additional medication use is needed. Throughout the study, participants undergo assessments including endoscopic nasal polyp scoring, nasal obstruction evaluation via a verbal response scale, symptom questionnaires like SNOT-22, CT scans, and asthma control tests. Researchers closely observe safety and treatment effects over one year, with participation lasting up to 52 weeks plus follow-up as needed.
CONDITIONS
Brief Title
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here